Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma
Mepolizumab treatment modifies the functional phenotype of eosinophils resulting in a lower percentage of iEOS and reduced activation status. These changes occur at an early time point (4 weeks) and are maintained throughout all treatment period.
Authors
- Christian Calvo‐Henríquez (ORCID: https://orcid.org/0000-0003-3580-0967)
- Pablo Miguéns‐Suárez (ORCID: https://orcid.org/0000-0003-0932-4397)
- Juan José Nieto‐Fontarigo (ORCID: https://orcid.org/0000-0002-4647-1508)
- Dolores Corbacho-Abelaira (ORCID: https://orcid.org/0000-0003-1239-5276)
- Uxío Calvo-Álvarez (ORCID: https://orcid.org/0000-0002-5243-2767)
- Sara Vázquez‐Mera (ORCID: https://orcid.org/0000-0002-4540-8013)
- Francisco J. Salgado (ORCID: https://orcid.org/0000-0003-4738-215X)
- Tamara Hermida-Valverde
- Mar Mosteiro (ORCID: https://orcid.org/0000-0003-0305-7179)
- Laura Martelo‐Vidal (ORCID: https://orcid.org/0000-0002-6303-0157)
- Marina Blanco‐Aparicio (ORCID: https://orcid.org/0000-0002-5012-1746)
- Francisco Javier González‐Barcala
- Coral González‐Fernández (ORCID: https://orcid.org/0000-0001-5897-7867)
Institutions
- Universidade da Coruña (ES)
- Universidade de Santiago de Compostela (ES)
- University Hospital Complex Of Vigo (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Center for Research in Molecular Medicine and Chronic Diseases (ES)
- Hospital Universitario Central de Asturias (ES)
- Povisa Hospital (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Complejo Hospitalario de Ourense (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1654111
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Xunta de Galicia
- Agencia Estatal de Investigación
- European Social Fund